immunoproliferative disorders
Post on 13-Nov-2014
2.765 Views
Preview:
DESCRIPTION
TRANSCRIPT
1
Immunoproliferative Disorders Neoplastic expansions of mature
Ab-secreting plasma cells give rise to:- Multiple myeloma Waldenstrom’s macroglobulinaemia Monoclonal gammopathy of unknown
significance Heavy chain disease
Tumors affecting plasma cells are often also referred to as plasma cell dyscrasias
2
Multiple Myeloma Is an abnormal proliferation of
malignant plasma cells typically characterized by
excessive production of an immunoglobulin molecule of single heavy and light chain type paraprotein
Most prevalent and clinically important plasma cell neoplasm
3
Multiple Myeloma Approx 4/100,000 of Western
Europeans and North Americans are diagnosed per year
It is twice as common in black Americans than white Americans
Median age of onset 60 years Men and women are equally
affected
4
Multiple Myeloma Median survival from diagnosis is
3 years, with a range up to 10 years
Environmental factors presumed to have an influence on the development of disease
Agricultural workers and those exposed to benzene and radiation have a higher incidence
5
Multiple Myeloma Patients present with symptoms arising
from lytic bone disease, anemia, renal failure or secondary Ab deficiency
20% of patients with MM are diagnosed by chance usually when liver function tests on a blood sample reveal an excessive concentration of total protein or gammaglobulins caused by excessive immunoglobulin production
6
Multiple MyelomaDiagnosis of MM and its remissionMajor criteria I. Plasmacytoma i.e. solid plasma cell
tumor II. Plasma cells in bone marrow
>30% III. Paraprotein level >35 g/l (IgG);
>20 g/l (IgA), or Bence Jones proteinuria >1 g in 24 hrs
7
Multiple MyelomaMinor criteria A. 10 – 30% plasma cells in bone
marrow B. Paraprotein present but less
than in III above C. Lytic bone lesions D. Suppression of normal
immunoglobulins (IgG <6 g/l, IgA <1 g/l or IgM <0.5 g/l)
8
Multiple MyelomaDiagnosis based on I or II plus one of b, c, or d III plus a, c or d A and b with either c or dFeatures of disease remission Serum paraprotein reduced by 75% Bence Jones proteinuria reduced by
95%
9
Multiple Myeloma Less than 5% plasma cells in bone
marrowTests in the diagnosis and managementTest Interpretation Serum Ig levels Evidence of
immune paresis Serum electrophoresis Identify and
quantify paraprotein; paresis of other
Ig isotypes
10
Multiple Myeloma Immunofixation Paraprotein
type Urine electrophoresis Bence Jones
proteinuria BM examination % plasma
cells; plasma cell clonality
Skeletal radiology Lytic bone lesions
11
Multiple Myeloma Calcium, urea, Hypercalcemia; electrolytes renal function Levels of 2 Prognostic
microglobulin marker Full blood count Anemia;
leucopenia; thrombocytopenia;
rouleaux; increased background staining
12
Multiple Myeloma Once the diagnosis is made, it is
generally accepted that patients with symptoms should commence treatment
In asymptomatic patients, treatment is started in the presence of a large tumor burden or may be delayed until symptoms arise
13
Multiple Myeloma There is a popular misconception
that the finding of a paraprotein or M band (M for myeloma) makes the diagnosis of MM
The presence of an M band alone is not diagnostic of MM and neither it is an absolute requirement to make the diagnosis
14
Multiple Myeloma In the majority of patients, there is
excessive production of free Ig light chains ( or ) by the malignant plasma cell, and these are of a sufficiently low molecular weight to be excreted in the urine Bence Jones proteinuria
15
Multiple MyelomaImmunological features Overproduction of a single Ig by a
malignant plasma cell clone >95% of patients will have evidence in
the serum or urine : light chain ratio of paraproteins in
patients reflects that of normal Ig (2:1) In the majority of patients (>60%),
malignant clone produce IgG, with 20% secreting IgA, and 2% IgD
16
Multiple Myeloma IgE myeloma is exceedingly rare In some patients (15%), only free light
chains are secreted No paraprotein is detected in 0.5% BM examination – an excess of plasma
cells by conventional staining techniques Can be stained using
immunofluorescence with specific antisera to or light chains revealing monoclonality of plasma cell expansion
17
Multiple Myeloma Paraproteins are identified by
serum electrophoresis Urine electrophoresis should
always be performed in parallel to identify light chains being excreted which are found in 50% of patients
The heavy and light chain type of a paraprotein are identified by immunofixation
18
Multiple Myeloma 2 microglobulin, the invariant part
of the class I HLA molecule acts as an independent prognostic indicator
A rising level is also an index of deteriorating renal function
As severe renal failure is frequently a fatal complication, serum 2
microglobulin is one of the best prognostic markers
19
Multiple MyelomaTreatment Intermittent courses of alkylating
agents (melphalan, cyclophosphamide) and a corticosteroid such as prednisolone have been the mainstays of therapy
For younger patients, more aggressive cytotoxic regimens are used with combination chemotherapy (vincristine, adriamycin, methylprednisolone:VAMP)
20
Multiple Myeloma Remission is typically achieved in
40% of patients Remission is maintained for a
median of 2 years although some may remain disease free for 10 yrs or more
New therapies have been evaluated to include other cytotoxic agents and IFN-, shown to prolong the plateau phase of disease
21
Multiple Myeloma BM ablation followed by allogeneic BM
transplantation is only recommended for recipients under 50 yrs of age with an HLA compatible sibling as a donor
Mortality is high with 15 – 20% of transplanted pts dying in the first 3 mo.
Autologous BM transplantation Harvesting marrow in early remission
followed by ablation therapy and reinfusing the original marrow cells
22
Multiple MyelomaSeveral important life-threatening
complications:- Lytic lesions seen in 60% of pts are
painful and may give rise to vertebral collapse with spinal cord damage or pathological fractures
Bone disease probably caused by IL-6, IL-1 and TNF- hypercalcaemia
23
Multiple Myeloma Renal damage evident in 50% of
pts at presentation, may be exacerbated by hypercalcaemia
Secondary Ab deficiency is common and gives rise to recurrent bacterial infections Prompt and prolonged use of
antibiotics is the treatment of choice Prophylactic IVIG replacement
therapy
24
Waldenstrom’s Macroglobulinaemia
Malignant expansion of mature B cells at the stage of IgM secretion
Can also be described as a slow-growing small-cell lymphocytic lymphoma
Median age of onset is 60 years Has a better prognosis than MM,
with median survival of 5 – 10 yrs
25
Waldenstrom’s Macroglobulinaemia
Typically small lymphocytes that stain IgM positive and express only a single light chain type are infiltrating the BM, LN and spleen
Being a pentamer, IgM has a high molecular weight, and high levels of circulating paraprotein produce a hyperviscosity syndrome
26
Waldenstrom’s Macroglobulinaemia
This manifests itself as fatigue, headaches, dizziness, visual disturbance and confusion
Hyperviscosity is treated by removal of the patient’s plasma and replacement with donor plasma or albumin plasmapheresis
Plasmapheresis may also be required if the paraprotein has the physicochemical properties of a cryoglobulin
27
Waldenstrom’s Macroglobulinaemia
High levels of paraprotein can also interfere with the function of other plasma proteins such as those of the clotting cascade producing a coagulopathy, with nose bleeds and bruising being common signs at presentation
28
Waldenstrom’s Macroglobulinaemia
Anemia is typically present and often more severe than in MM
Bence Jones proteinuria is only found in 10% of pts
Bone lesions are rare
29
Waldenstrom’s Macroglobulinaemia
Therapy involves use of alkylating agents chlorambucil and cyclophosphamide, administered with corticosteroids and accompanied by regular monitoring of paraprotein levels
Younger pts may be suitable for more aggressive therapy, with autologous or allogeneic BM transplantation
30
Monoclonal Gammopathy of
Unknown Significance
Frequently, high levels of gammaglobulins or total protein detected in routine screening result in the identification of a paraprotein, but the diagnostic criteria for MM are not met
31
Monoclonal Gammopathy of
Unknown Significance In these cases, a diagnosis of
monoclonal gammopathy of unknown significance (MGUS) may be made if the patient is asymptomatic; the paraprotein levels are below 35 g/l for IgG and 20 g/l for IgA; there are no Bence Jones proteins in urine (<1g/24 hrs free light chains); there are <10% plasma cells in the BM; and there are no bone lesions
32
Monoclonal Gammopathy of
Unknown Significance
Frequency of MGUS goes as high as 3% of the population over the age of 50 yrs
In some cases, condition is pre-malignant and the conversion rate to frank myeloma is of the order of 1% of pts per yr
A similar proportion of pts will progress to WM or amyloidosis
33
Monoclonal Gammopathy of
Unknown Significance
Regular monitoring of these patients for evidence of marrow suppression, increasing level of paraprotein and depression of normal Ig production is advisable
34
Monoclonal Gammopathy of
Unknown Significance
One interesting complication is the presence of a monoclonal paraprotein with specificity for the peripheral nerve component myelin-associated glycoprotein giving rise to peripheral neuropathy
35
Heavy Chain Disease
There are rare B lymphocyte lymphoproliferative disorders in which only heavy chains are produced by the malignant cells
Typically it is the Fc region alone that is produced and in the majority of patients described to date, this has been the heavy chain
36
Heavy Chain Disease
There are approximately 100 reported pts with heavy chain disease and even fewer involving production of chains
In most pts, the level of paraprotein is very low and the diagnosis difficult to make
37
Heavy Chain Disease
The heavy chain disease is the best characterized and appears to be a pre-malignant syndrome in which young pts of Mediterranean origin present with upper GI symptoms (pain, diarrhoea, fever and weight loss)
The condition may respond to antibiotics or may progress to a lymphomatous condition
38
Heavy Chain Disease
A high degree of intestinal infestation with microorganisms has been suggested as the aetiological factor in this condition, but no single organism has been identified to date.
top related